In the BioHarmony Drug Report Database
Anidulafungin
Eraxis, Ecalta (anidulafungin) is a small molecule pharmaceutical. Anidulafungin was first approved as Eraxis on 2006-02-17. It is used to treat abdominal abscess, candidemia, mycoses, and peritonitis in the USA. It has been approved in Europe to treat candidiasis. Eraxis’s patent is valid until 2021-04-12 (FDA).
Trade Name
|
Ecalta |
|---|---|
Common Name
|
anidulafungin |
ChEMBL ID
|
CHEMBL264241 |
Indication
|
abdominal abscess, candidemia, candidiasis, mycoses, peritonitis |
Drug Class
|
Antifungal antibiotics (undefined group) |
Image (chem structure or protein)